Zacks Research Equities Analysts Reduce Earnings Estimates for Pfizer Inc. (NYSE:PFE)

Pfizer Inc. (NYSE:PFE - Free Report) - Zacks Research decreased their Q3 2025 earnings estimates for shares of Pfizer in a report issued on Monday, September 23rd. Zacks Research analyst K. Shah now expects that the biopharmaceutical company will post earnings per share of $0.72 for the quarter, down from their previous estimate of $0.73. The consensus estimate for Pfizer's current full-year earnings is $2.66 per share.

PFE has been the topic of several other reports. StockNews.com upgraded shares of Pfizer from a "hold" rating to a "buy" rating in a research report on Thursday, August 1st. Cantor Fitzgerald restated an "overweight" rating and set a $45.00 target price on shares of Pfizer in a report on Monday, September 16th. Daiwa America raised Pfizer from a "moderate buy" rating to a "strong-buy" rating in a report on Wednesday, August 7th. Daiwa Capital Markets raised Pfizer from a "neutral" rating to an "outperform" rating and raised their price objective for the stock from $28.00 to $34.00 in a research note on Wednesday, August 7th. Finally, Wells Fargo & Company boosted their target price on Pfizer from $28.00 to $30.00 and gave the stock an "equal weight" rating in a research report on Wednesday, July 31st. Eight investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $34.54.

Pfizer Price Performance

Shares of PFE traded up $0.21 during midday trading on Tuesday, reaching $29.52. The stock had a trading volume of 21,431,181 shares, compared to its average volume of 37,782,941. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. The company has a market capitalization of $167.25 billion, a P/E ratio of -491.83, a P/E/G ratio of 1.05 and a beta of 0.68. The firm's 50 day moving average price is $29.36 and its 200-day moving average price is $28.28. Pfizer has a 52 week low of $25.20 and a 52 week high of $34.11.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating analysts' consensus estimates of $0.46 by $0.14. The business had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business's revenue for the quarter was up 2.1% on a year-over-year basis. During the same quarter last year, the business earned $0.67 earnings per share.

Institutional Investors Weigh In On Pfizer

A number of institutional investors have recently modified their holdings of the stock. Wellington Management Group LLP raised its holdings in shares of Pfizer by 4.9% during the fourth quarter. Wellington Management Group LLP now owns 239,209,768 shares of the biopharmaceutical company's stock worth $6,886,849,000 after acquiring an additional 11,099,024 shares in the last quarter. Marshall Wace LLP raised its stake in shares of Pfizer by 279.3% during the 2nd quarter. Marshall Wace LLP now owns 5,378,173 shares of the biopharmaceutical company's stock worth $150,481,000 after purchasing an additional 8,378,173 shares in the last quarter. Swedbank AB acquired a new stake in shares of Pfizer during the 1st quarter valued at about $172,902,000. Pzena Investment Management LLC grew its stake in shares of Pfizer by 181.6% in the 1st quarter. Pzena Investment Management LLC now owns 7,670,445 shares of the biopharmaceutical company's stock valued at $212,855,000 after buying an additional 4,947,000 shares in the last quarter. Finally, Ruffer LLP raised its position in Pfizer by 248.7% during the fourth quarter. Ruffer LLP now owns 5,796,012 shares of the biopharmaceutical company's stock valued at $166,837,000 after acquiring an additional 4,133,786 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th were paid a $0.42 dividend. The ex-dividend date of this dividend was Friday, July 26th. This represents a $1.68 annualized dividend and a yield of 5.69%. Pfizer's dividend payout ratio is presently -2,799.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.